Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Profound Medical Corp. (PRN.TO)
CAD9.88
-0.10 (-1.00%)
CA TSX Healthcare Medical - Devices
Address
2400 Skymark Avenue L4W 5K5
Mississauga, ON, CA
Mississauga, ON, CA
CEO
Arun Swarup Menawat
Website
profoundmedical.com
IPO
2018-07-10
ISIN CA74319B5027
Also trades on
NASDAQ Capital Market · PROF (USD)
Toronto Stock Exchange · PRN.TO (CAD)
Description
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD9.88
-0.10 (-1.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11.8K
Beta
0.53
Float Shares
29.02M
Free Float %
95.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.93% | -0.82% | +13.63% | +8.65% | +6.97% | -10.21% | +62.52% | -43.38% | -52.69% | -3.30% | -3.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
9.88
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.33
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+110.6% ★ Q1'26: +179.3% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-75.9% Q1'26: +25.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-266.1% Q1'26: -160.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-256.3% Q1'26: -150.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-368.1% Q1'26: -190.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+22.1% Q1'26: +20.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.11× Q1'26: -0.24× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 437.6K (-100.0%)
|
3.90M
est: 4.05M (-3.7%)
|
1.91M
est: 1.75M (+9.0%)
|
4.23M
est: 4.08M (+3.8%)
|
7.30M
est: 6.36M (+14.9%)
|
6.87M
est: 9.49M (-27.6%)
|
6.68M
est: 8.17M (-18.3%)
|
7.20M
est: 7.10M (+1.5%)
|
10.68M
est: 11.23M (-4.9%)
|
22.49M
est: 17.57M (+28.0%)
|
27.54M
23.95M – 29.53M
+56.7% YoY
|
45.74M
41.44M – 48.67M
+66.1% YoY
|
74.54M
66.49M – 79.54M
+63.0% YoY
|
104.23M
92.97M – 111.21M
+39.8% YoY
|
147.22M
131.32M – 157.09M
+41.3% YoY
|
| EBITDA |
-15.56M
est: -437.6K (-3,456.3%)
|
-16.78M
est: -4.05M (-314.4%)
|
-13.24M
est: -1.75M (-655.7%)
|
-12.53M
est: -4.08M (-207.3%)
|
-19.50M
est: -6.36M (-206.7%)
|
-28.65M
est: -9.49M (-201.9%)
|
-34.63M
est: -8.17M (-323.7%)
|
-27.00M
est: -7.10M (-280.5%)
|
-32.13M
est: -11.23M (-186.2%)
|
-56.86M
est: -17.57M (-223.6%)
|
-27.54M
-29.53M – -23.95M
-56.7% YoY
|
-45.74M
-48.67M – -41.44M
-66.1% YoY
|
-74.54M
-79.54M – -66.49M
-63.0% YoY
|
-104.23M
-111.21M – -92.97M
-39.8% YoY
|
-147.22M
-157.09M – -131.32M
-41.3% YoY
|
| EBIT |
-15.75M
est: -437.6K (-3,499.0%)
|
-13.84M
est: -4.05M (-241.8%)
|
-14.32M
est: -1.75M (-717.2%)
|
-14.04M
est: -4.08M (-244.3%)
|
-21.03M
est: -6.36M (-230.9%)
|
-30.53M
est: -9.49M (-221.8%)
|
-28.21M
est: -8.17M (-245.1%)
|
-27.93M
est: -7.10M (-293.6%)
|
-33.06M
est: -11.23M (-194.5%)
|
-57.64M
est: -17.57M (-228.0%)
|
-27.54M
-29.53M – -23.95M
-56.7% YoY
|
-45.74M
-48.67M – -41.44M
-66.1% YoY
|
-74.54M
-79.54M – -66.49M
-63.0% YoY
|
-104.23M
-111.21M – -92.97M
-39.8% YoY
|
-147.22M
-157.09M – -131.32M
-41.3% YoY
|
| Net Income |
-12.15M
est: -62.26M (+80.5%)
|
-14.97M
est: -48.89M (+69.4%)
|
-15.24M
est: -38.66M (+60.6%)
|
-15.46M
est: -33.55M (+53.9%)
|
-21.62M
est: -26.60M (+18.7%)
|
-30.70M
est: -31.31M (+1.9%)
|
-28.67M
est: -32.36M (+11.4%)
|
-28.57M
est: -30.04M (+4.9%)
|
-27.82M
est: -37.63M (+26.1%)
|
-59.48M
est: -41.20M (-44.4%)
|
-25.37M
-33.44M – -21.40M
+38.4% YoY
|
-21.99M
-45.72M – -8.25M
+13.3% YoY
|
3.26M
2.80M – 3.54M
+114.8% YoY
|
16.59M
14.26M – 18.04M
+409.1% YoY
|
29.63M
25.47M – 32.22M
+78.6% YoY
|
| SGA |
4.20M
est: 1.03M (+308.8%)
|
7.84M
est: 9.52M (-17.6%)
|
7.89M
est: 4.12M (+91.6%)
|
8.01M
est: 9.58M (-16.4%)
|
12.43M
est: 14.94M (-16.8%)
|
17.97M
est: 22.30M (-19.4%)
|
17.93M
est: 19.21M (-6.7%)
|
18.62M
est: 16.68M (+11.7%)
|
23.13M
est: 27.03M (-14.4%)
|
44.78M
est: 42.32M (+5.8%)
|
66.33M
57.68M – 71.11M
+56.7% YoY
|
110.17M
99.80M – 117.21M
+66.1% YoY
|
179.53M
160.14M – 191.56M
+63.0% YoY
|
251.02M
223.91M – 267.85M
+39.8% YoY
|
354.57M
316.27M – 378.34M
+41.3% YoY
|
| EPS |
-2.93
est: -2.51 (-16.6%)
|
-2.44
est: -1.97 (-23.6%)
|
-1.52
est: -1.56 (+2.6%)
|
-1.39
est: -1.35 (-2.6%)
|
-1.25
est: -1.07 (-16.4%)
|
-1.50
est: -1.26 (-18.7%)
|
-1.38
est: -1.31 (-5.6%)
|
-1.35
est: -1.23 (-10.0%)
|
-1.12
est: -1.24 (+9.9%)
|
-1.97
est: -1.37 (-44.3%)
|
-0.84
-1.11 – -0.71
+38.5% YoY
|
-0.73
-1.51 – -0.27
+13.3% YoY
|
0.11
0.09 – 0.12
+114.8% YoY
|
0.55
0.47 – 0.60
+409.1% YoY
|
0.98
0.84 – 1.07
+78.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-42.30M
OE per share TTM
-1.34
Owner's Yield
-11.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
17.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 6.7K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-4.1K
Shares Outstanding
30.26M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arun Swarup Menawat | Chairman of the Board & Chief Executive Officer | 1M | — |
| Mathieu Burtnyk | President | 656.2K | — |
| Rashed Dewan | Chief Financial Officer | 645.8K | male |
| Thomas Tamberrino | Chief Commercial Officer | 522.7K | male |
| Matthew Sobczyk | Assistant Corporate Controller | — | male |
| Levant Tinaz | Software Developer | — | male |
| Stephen Kilmer | Investor Relations | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRN.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
